Cas:94192-59-3 N-cyclohexyl-N-methyl-4-[(2-oxo-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide manufacturer & supplier

Chemical Name:N-cyclohexyl-N-methyl-4-[(2-oxo-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide

CAS.NO:94192-59-3

Synonyms:Lixazinonum [Latin];Butanamide,N-cyclohexyl-N-methyl-4-((1,2,3,5-tetrahydro-2-oxoimidazo(2,1-b)quinazolin-7-yl)oxy);Lixazinonum;Butanamide,N-cyclohexyl-N-methyl-4-((2-oxo-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-7-yl)oxy);Lixazinone;N-cyclohexyl-N-methyl-4-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxybutyramide;Lixazinona;Lixazinona [Spanish];Lixazinone [INN]

Molecular Formula:C₂₁H₂₈N₄O₃

Molecular Weight:384.47200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:579.2ºC at 760 mmHg

Density:1.33g/cm3

Index of Refraction:1.659

PSA:74.24000

Exact Mass:384.21600

LogP:2.27190

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Lixazinonum [Latin] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Lixazinone [INN] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Lixazinona [Spanish] Use and application,Lixazinone technical grade,usp/ep/jp grade.

Related News: We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� N-cyclohexyl-N-methyl-4-[(2-oxo-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide manufacturer Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. N-cyclohexyl-N-methyl-4-[(2-oxo-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide supplier We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� N-cyclohexyl-N-methyl-4-[(2-oxo-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide vendor We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� N-cyclohexyl-N-methyl-4-[(2-oxo-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide factory Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.